CDH1 and breast carcinoma: In fact, exome sequencing studies revealed that PIK3CA mutations were as frequent as CDH1 mutations in lobular carcinoma in situ, but they were not a useful biomarker of progression, as they were as frequent in pure in situ lobular cancer as in lobular cancer in situ associated with invasive lobular carcinoma [291].